Zeleciment rostudirsen (z-rostudirsen)

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Administration

1 evidence topic · 1 source

Investigational route of administration

“Intravenous use” (opens the source at this quote in a new tab)

Final administration-site requirements

No evidence found.